https://orcid.org/0000-0003-3776-2407
Overview
Based on my prior experience in basic/translational immunology research and clinical hematopoietic stem cell transplantation, I am interested in early phase clinical protocols for novel immunotherapy of hematologic malignancies.
Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2019 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteImpact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.
Journal article Bone Marrow Transplant · June 2026 Full text Link to item CiteMusculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.
Journal article Transplant Cell Ther · May 2026 Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). While life-threatening toxicities like cytokine release syndrome and immune effector c ... Full text Link to item CiteRecent Grants
Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2029A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2028BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2022 - 2027View All Grants
Education
Seoul National University (South Korea) ·
2002
M.D.